Ascentage Pharma announces first patient dosed in Phase I clinical trial of APG-2575 in China as the first China-made Bcl-2 Inhibitor
(WorldNews Health)

SUZHOU, China and ROCKVILLE, Md., July 14, 2019 /PRNewswire/ -- Ascentage Pharma, a globally-focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, hepatitis B virus and age-related diseases, today announced that the company recently dosed the first patient successfully in a Phase I clinical trial of APG-2575, a novel Bcl-2 selective inhibitor, for the treatment of hematologic malignancies in China. The Company also has an ongoing multi-center Phase I dose-escalation study of APG-2575 as a single agent in the United States and Australia. APG-2575 could potentially be the first China-made Bcl-2 inhibitor. APG-2575 is a novel, orally...